Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 6.3 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), an at-the-market (ATM) program filed Jul 17, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$15.8MCash on Hand
6.3mo Cash Runway
Follow TVRD by emailGet an email when TVRD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TVRD, unsubscribe in one click. Privacy
📣 What TVRD Says Is Next
first quarter of 2027 · TTI-101: “The Company expects to report topline data early in the first quarter of 2027 to allow for complete cohort evaluation.”
Company press release, Nov 13, 2026 · SEC filing
third quarter of 2027 · “Tvardi anticipates that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations, as currently planned, through the HCC topline readout into the third quarter of 2027.”
Company press release, Aug 14, 2026 · SEC filing
in 2027 · “This is what led us to prioritize UC as our initial indication for TTI-109.” Planned UC Clinical Trial Tvardi plans to initiate a study of TTI-109 in patients with moderate-to-severe UC in 2027, subject to clearance of Investigational New Drug (IND) application and additional funding.”
Company press release, Jul 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 net loss of $6.1 million, or $(0.48) per share, versus $5.5 million a year earlier, with R&D rising to $4.5 million. Cash was $22.3 million, enough to fund operations into Q3 2027. TTI-101 HCC topline data expected early Q1 2027. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Earnings Reported Q2 2026 net loss of $6.5 million, or $(0.69) per share, versus net income of $4.2 million a year earlier, and cash of $15.8 million as of June 30, 2026. Announced ulcerative colitis as the initial indication for TTI-109 and a KOL webinar on August 19, 2026. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 1/2 · Recruiting · A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not TVRD's own candidates): Atezolizumab, Bevacizumab, Pembrolizumab, Fulvestrant, Palbociclib, Ribociclib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TVRD holds $15.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.5M/quarter from operations,
an estimated runway of 6.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:84 · High
Cash runway 6 months +30
ATM program on file since Jul 2026 +15
Shelf registration (S-3, May 2026) +10
Going-concern doubt in the latest 10-Q +15Management has determined that its present capital resources as of September 30, 2026 will not be sufficient to fund its planned operations for at least one year from the issuance date of the unaudited condensed consolidated financial statements, included elsewhere in this Quarterly Report, which raises substantial…10-Q, Nov 2026
Share count 13,363,391 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TVRD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVRD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.